The combination of ATO and FLT3 TKI resulted in potent inhibition on downstream targets of FLT3 signaling in FLT3/ITD+ leukemia samples, as was seen previously for the FLT3/ITD+ cell lines (Figure 7E). This evidence concerns the gene FLT3 and leukemia.